Eric Roux Email and Phone Number

Responsible for all Commercial operations in the Northeast Area of the US.

Immertec, the only live 3D ImmersiveReal Time Streaming Platform for training, proctoring and educating from anywhere to anywhere. Our patented technology allows for anybody to be IMMERSED into the live surgery or bio-skills environment for a learning experience that is unlike any other.

Pear Therapeutics is the First Ever FDA Authorized Prescription Digital Therapeutics (PDT's). The first 2 therapies help fight the epidemic of SUD and OUD. Pear is a platform technology with the ability to provide a suite of therapies across multiple diseases in the future.

OmniGuide's revolutionary technology disrupted the CO2 Surgical space for such specialties as Head & Neck Cancer, OB-Gyn, Spine Surgery and General Surgery. During my time at OmniGuide we successfully launched several new technologies, acquired and merged two existing companies (OmniGuide and Domain Surgical) into an industry leading advanced energy company and redeployed the commercial team to transition from a disposable focused to capital driven sales team.

Led Eastern US Area in all aspects of strategy, execution and results. Hired, developed and managed high performing teams during a record 3 years of company growth were executed. Worked cross functionally integrating with areas such as regulatory, marketing, engineering, professional education and sales training to develop and launch new products, markets, and scale organization.

Responsible for developing the Eastern Area team for the introduction and growth of revolutionary, disruptive technology (TMS) to treat major depression. Company successfully launched and established 400+ systems across the US prior to any reimbursement. Subsequently, Neuronetics has successfully accomplished an Initial Public Offering (IPO) under the Nasdaq symbol "STIM"

Introduced revolutionary XLIF Procedure to the Spine Market in New England, an area which in the previous years had only completed a single surgeon that had done an XLIF. Now there are over 30 trained surgeons regularly using lateral technique.

Introduced revolutionary Kyphoplasty procedure into the New England market and helped establish it as a now standard of care treatment. Involved when started as a private VC backed company to IPO and eventual MDT acquisition for over $4 Billion.

Established Boston market for cutting edge hemodynamic devices for use in cardiac surgery and critical care